These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32184332)

  • 1. Reply to Zhao et al.: NOMO1 is a potential target gene of MRTFB.
    Marian TA; Wei Z
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7570-7571. PubMed ID: 32184332
    [No Abstract]   [Full Text] [Related]  

  • 2. MRTFB regulates the expression of NOMO1 in colon.
    Zhao T; Hu Y; Zang T; Cheng L
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7568-7569. PubMed ID: 32184333
    [No Abstract]   [Full Text] [Related]  

  • 3. MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM.
    Kodama T; Marian TA; Lee H; Kodama M; Li J; Parmacek MS; Jenkins NA; Copeland NG; Wei Z
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23625-23635. PubMed ID: 31690663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to the letter to the editor 'A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma' by Rosati et al.
    Hines RB; Al-Rajabi R
    Ann Oncol; 2016 May; 27(5):957-8. PubMed ID: 26811349
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to M. Løberg et al.
    Bains SJ; Mahic M; Myklebust TÅ; Småstuen MC; Yaqub S; Dørum LM; Bjørnbeth BA; Møller B; Brudvik KW; Taskén K
    J Clin Oncol; 2017 Feb; 35(5):569-571. PubMed ID: 29236616
    [No Abstract]   [Full Text] [Related]  

  • 6. NOMO-1 gene is deleted in early-onset colorectal cancer.
    Perea J; García JL; Pérez J; Rueda D; Arriba M; Rodríguez Y; Urioste M; González-Sarmiento R
    Oncotarget; 2017 Apr; 8(15):24429-24436. PubMed ID: 28416736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling.
    Liu D; Du L; Chen D; Ye Z; Duan H; Tu T; Feng J; Yang Y; Chen Q; Yan X
    Oncotarget; 2016 Jun; 7(26):40704-40718. PubMed ID: 27302922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of nodal modulator 1 inhibits the differentiation of P19 cells into cardiomyocytes.
    Zhang H; Xu C; Yang R; Chen H; Kong X; Qian L; Sheng Y; Sun W
    Exp Cell Res; 2015 Feb; 331(2):369-76. PubMed ID: 25576386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Katona et al.
    Oh M; McBride A; Yun S; Bhattacharjee S; Slack M; Martin JR; Jeter J; Abraham I
    J Natl Cancer Inst; 2019 May; 111(5):524-525. PubMed ID: 30715401
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Chiu et al. And Lasa et al.
    Reinhart K; Ferlitsch M
    Endoscopy; 2013 Dec; 45(12):1056. PubMed ID: 24288226
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
    Yoshino T; Hsu Y; Nasroulah F
    Eur J Cancer; 2018 Mar; 92():121-122. PubMed ID: 29433790
    [No Abstract]   [Full Text] [Related]  

  • 12. Author commentary on Emma C. Robbins et al.
    Endoscopy; 2021 Apr; 53(4):v19. PubMed ID: 33780981
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: Colorectal cancer in relatives of patients with common colorectal cancer - author's reply.
    Samadder NJ
    Aliment Pharmacol Ther; 2015 May; 41(10):1026-7. PubMed ID: 25881924
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to Yang, Shi, Wang et al.
    Oh M; McBride A; Yun S; Bhattacharjee S; Slack M; Martin JR; Jeter J; Abraham I
    J Natl Cancer Inst; 2020 Apr; 112(4):428. PubMed ID: 31424546
    [No Abstract]   [Full Text] [Related]  

  • 15. The Optimal Body Mass Index Range for Patients With Colorectal Cancer-Reply.
    Kroenke CH; Caan BJ; Prado C
    JAMA Oncol; 2017 May; 3(5):708. PubMed ID: 28006060
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of Recurrence-Predictive Indicators in Stage I Colorectal Cancer: Reply.
    Lee JH; Lee JL; Kim JC
    World J Surg; 2017 Jun; 41(6):1658-1659. PubMed ID: 28321557
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to Zhang et al.
    Backes Y; Moss A; Reitsma JB; Siersema PD; Moons LM
    Am J Gastroenterol; 2017 Mar; 112(3):514-515. PubMed ID: 28270673
    [No Abstract]   [Full Text] [Related]  

  • 18. CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion.
    Ouhtit A; Abdraboh ME; Hollenbach AD; Zayed H; Raj MHG
    Cell Commun Signal; 2017 Nov; 15(1):45. PubMed ID: 29121955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to S. Sorscher.
    Innocenti F; Ou FS; Qu X; Zemla T; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
    J Clin Oncol; 2019 Sep; 37(25):2291-2293. PubMed ID: 31268798
    [No Abstract]   [Full Text] [Related]  

  • 20. Video Comment on Katsuro Ichimasa et al.
    Endoscopy; 2018 Mar; 50(3):v12. PubMed ID: 29482239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.